Ann: Update on Fast Track of Phase I Clinical Trials, page-3

Bod has engaged with highly credible counter parties to source and develop its clinical trial program as follows:
▪ Cannabis extract – globally unique, phytocomplex cannabis extract, sourced from Swiss company Linnea owned by Schwabe and Ipsen (EPA:IPN – Market Cap €8.9Bn)
▪ Delivery method – exclusively sourced from innovative late-stage specialty pharmaceutical company iX Biopharma Ltd (SGX:42C – Market Cap ~SGD$120m)
▪ Clinical trial program – formulation, design and dosage determined by ex-head of global clinical trials of Sirtex Medical Ltd (ASX:SRX – Market Cap ~A$880m)

Our market cap is still sweet FA compared to these other players - could be a long run up from here!

GLTAH